HIGHLIGHTS
SUMMARY
Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal tumor that originates from the internal bile ducts of the liver. High α-SMA expression in iCCA human tissues is correlated with the worst prognosis and poorer survival outcomes in iCCA patients following surgical resection. The authors have reported that Crenigacestat inhibits the growth of iCCA in PDX and xenograft models by modulating angiogenesis and/or the expression of stemness marker CD90. In conclusion, according to the bioinformatic analysis and experimental results, Crenigacestat inhibits Notch signaling and TGF-β1 associated with dephosphorylation of SMAD2/3. The authors have . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.